Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01671787 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT01671787 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 51 participants.
The verdict
NCT01671787, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
This is an open-label study evaluating multiple doses of GS-7340 versus Tenofovir disoproxil fumarate (TDF).
Interventions
- DRUG Tenofovir disoproxil fumarate
- DRUG GS-7340
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01671787
The ClinicalTrials.gov registry entry for NCT01671787 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tenofovir disoproxil fumarate is the first listed.
NCT01671787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01671787 about?
NCT01671787 is a clinical study titled "A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B". This is an open-label study evaluating multiple doses of GS-7340 versus Tenofovir disoproxil fumarate (TDF).
What is the current status of trial NCT01671787?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2012-03. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01671787?
The interventions under investigation include: Tenofovir disoproxil fumarate (DRUG), GS-7340 (DRUG).
Who is sponsoring clinical trial NCT01671787?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.